CSIMarket
 


Cryoport inc   (CYRX)
Other Ticker:  
 
 

CYRX's Capital Expenditures Growth by Quarter and Year

Cryoport Inc 's Capital Expenditures results by quarter and year




CYRX Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 12.24 8.46 8.54 2.62
III Quarter September 11.49 5.75 9.20 1.99
II Quarter June 10.96 5.39 4.21 0.63
I Quarter March 10.21 4.60 3.05 1.17
FY   44.90 24.20 25.00 6.41



CYRX Capital Expenditures fourth quarter 2023 Y/Y Growth Comment
Cryoport inc reported Capital Expenditures rise of 44.7% year on year in the fourth quarter 2023, to $ 12.24 millions, this is lower than Cryoport Inc 's recent average Capital Expenditures surge of 132.22%.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Capital Expenditures growth. While Cryoport Inc ' s Capital Expenditures jump of 44.7% ranks overall at the positon no. 875 in the fourth quarter 2023.




CYRX Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 44.7 % -0.94 % 225.95 % 61.73 %
III Quarter September 99.83 % -37.5 % 362.31 % 34.46 %
II Quarter June 103.34 % 28.03 % 568.25 % -44.74 %
I Quarter March 121.96 % 50.82 % 160.68 % 7.34 %
FY   85.55 % -3.2 % 290.02 % 20.26 %

Financial Statements
Cryoport Inc 's fourth quarter 2023 Capital Expenditures $ 12.24 millions CYRX's Income Statement
Cryoport Inc 's fourth quarter 2022 Capital Expenditures $ 8.46 millions Quarterly CYRX's Income Statement
New: More CYRX's historic Capital Expenditures Growth >>


CYRX Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December 6.54 % 47.13 % -7.17 % 31.66 %
III Quarter September 4.84 % 6.68 % 118.53 % 215.87 %
II Quarter June 7.35 % 17.17 % 38.03 % -46.15 %
I Quarter March 20.69 % -46.14 % 16.41 % -27.78 %
FY (Year on Year)   85.55 % -3.2 % 290.02 % 20.26 %




Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #102
Overall #875

Capital Expenditures Y/Y Growth Statistics
High Average Low
1146.32 % 132.22 % -76.51 %
(Mar 31 2019)   (Mar 31 2018)
Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #102
Overall #875
Capital Expenditures Y/Y Growth Statistics
High Average Low
1146.32 % 132.22 % -76.51 %
(Mar 31 2019)   (Mar 31 2018)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Cryoport Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
4709.78 % 149.15 % -100 %
(Jun 30 2015)  


CYRX's IV. Quarter Q/Q Capital Expenditures Comment
Cryoport inc achieved in the IV. Quarter 2023 below company average Capital Expenditures increase of 6.54% quarter on quarter, to $ 12.24 millions.

Within Major Pharmaceutical Preparations industry 39 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Cryoport Inc 's Capital Expenditures growth quarter on quarter, overall rank is 931.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #40
Healthcare Sector #140
Overall #931
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #40
Healthcare Sector #140
Overall #931
Capital Expenditures Q/Q Growth Statistics
High Average Low
4709.78 % 149.15 % -100 %
(Jun 30 2015)  


CYRX's IV. Quarter Q/Q Capital Expenditures Comment
Cryoport inc achieved in the IV. Quarter 2023 below company average Capital Expenditures increase of 6.54% quarter on quarter, to $ 12.24 millions.

Within Major Pharmaceutical Preparations industry 39 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Cryoport Inc 's Capital Expenditures growth quarter on quarter, overall rank is 931.


Cryoport Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Capital Expenditures 12 Months Ending $ 44.90 $ 41.12 $ 35.38 $ 29.81 $ 24.20
Y / Y Capital Expenditures Growth (TTM) 85.56 % 69.39 % 27.62 % 12.27 % -3.24 %
Year on Year Capital Expenditures Growth Overall Ranking # 919 # 565 # 143 # 106 # 111
Seqeuential Capital Expenditures Change (TTM) 9.19 % 16.22 % 18.7 % 23.2 % -0.33 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 875 # 1666 # 1244 # 1269 # 968




Cumulative Capital Expenditures growth Comment
Although Cryoport Inc 's Annual Capital Expenditures growth year on year were below company's average 132.22% , Capital Expenditures announced in the Dec 31 2023 period, show improvement in Capital Expenditures trend, to cumulative trailing twelve month growth of 85.56% year on year, from 69.39% in Sep 30 2023.

In the Healthcare sector 108 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 565 to 919.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1146.32 %
132.22 %
-76.51 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 32
Healthcare Sector # 109
Overall # 919

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
1146.32 %
132.22 %
-76.51 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 32
Sector # 102
S&P 500 # 875
Cumulative Capital Expenditures growth Comment
Although Cryoport Inc 's Annual Capital Expenditures growth year on year were below company's average 132.22% , Capital Expenditures announced in the Dec 31 2023 period, show improvement in Capital Expenditures trend, to cumulative trailing twelve month growth of 85.56% year on year, from 69.39% in Sep 30 2023.

In the Healthcare sector 108 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 565 to 919.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1146.32 %
132.22 %
-76.51 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 32
Healthcare Sector # 109
Overall # 919

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
1146.32 %
132.22 %
-76.51 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 32
Sector # 102
S&P 500 # 875




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
CYRX's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for CYRX's Competitors
Capital Expenditures Growth for Cryoport Inc 's Suppliers
Capital Expenditures Growth for CYRX's Customers

You may also want to know
CYRX's Annual Growth Rates CYRX's Profitability Ratios CYRX's Asset Turnover Ratio CYRX's Dividend Growth
CYRX's Roe CYRX's Valuation Ratios CYRX's Financial Strength Ratios CYRX's Dividend Payout Ratio
CYRX's Roa CYRX's Inventory Turnover Ratio CYRX's Growth Rates CYRX's Dividend Comparisons



Companies with similar Capital Expenditures increase for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2023
Elanco Animal Health Inc77.22%$ 77.215 millions
Arrowhead Pharmaceuticals Inc 76.44%$ 76.444 millions
Renovaro Inc 75.96%$ 75.957 millions
Neuronetics inc 74.75%$ 74.751 millions
Integra Lifesciences Holdings Corp69.72%$ 69.722 millions
Bausch and Lomb Corp68.00%$ 68.000 millions
Entera Bio Ltd 66.67%$ 66.667 millions
Perrigo Company Plc65.84%$ 65.839 millions
Regeneron Pharmaceuticals Inc 65.18%$ 65.177 millions
Anaptysbio Inc 60.00%$ 60.000 millions
Cadre Holdings Inc 59.32%$ 59.319 millions
Co diagnostics Inc 58.40%$ 58.403 millions
Macrogenics Inc 57.76%$ 57.761 millions
Caribou Biosciences Inc 56.28%$ 56.280 millions
Privia Health Group Inc 53.33%$ 53.333 millions
National Healthcare Corp52.58%$ 52.581 millions
Ani Pharmaceuticals Inc52.10%$ 52.101 millions
Avantor Inc 50.60%$ 50.595 millions
Bausch Health Companies Inc 50.00%$ 50.000 millions
Gh Research Plc49.25%$ 49.254 millions
Cryoport inc 44.64%$ 44.636 millions
Hologic Inc43.67%$ 43.671 millions
Viemed Healthcare Inc 42.59%$ 42.588 millions
Laboratory Corporation Of America Holdings41.82%$ 41.815 millions
Livanova Plc41.44%$ 41.439 millions
Revance Therapeutics Inc 38.12%$ 38.121 millions
Entrada Therapeutics Inc 37.85%$ 37.853 millions
Beigene ltd 37.54%$ 37.536 millions
Inari Medical Inc 34.98%$ 34.983 millions
Henry Schein Inc34.48%$ 34.483 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com